- MeVis Medical Solutions
- Investor Relations
- IR Announcements
The German government has introduced tougher standards for organized markets (General Standard and Prime Standard) to reinforce long-term investor confidence and enhance capital market transparency.
For example, information about who owns how many shares of a company, or who holds the voting power, is important for ensuring transparent securities trading. If investors know about major buy and sell positions on the market, their own investment decisions are more informed and the potential misuse of inside information is restricted. Sections 21 and 22 of the German Securities Trading Act (WpHG) therefore require natural persons and legal entities to notify BaFin and the listed company of the amount of their voting shares as soon as these exceed or fall below thresholds of 3, 5, 10, 15, 20, 25, 30, 50 oder 75 percent of the voting rights.
Share transactions by members of the Executive and Supervisory Boards of listed companies (directors’ dealings) involving the company’s own securities are indicators of future business prospects for the market. They must therefore be disclosed without delay basically in accordance with section 15a of the WpHG. Publication of these transactions helps to prevent insider trading.
Mandatory announcements on information that could influence the price of MeVis shares (section 15 of the German Securities Trading Act, the WpHG) .
Disclosures of voting rights according to Article 26 paragraph 1 WpHG
Notification concerning transactions by persons performing managerial responsibilities according to Article 15a WpHG
Other announcements according to further German and EU-regulations
Annual documents about all infomartion published by the company during a financial year according to Sections 15, 15a, 26, 30b Paragr. 1 and 2, Sections 30e, 30f Paragr. 2, Sections 37v, 37w, 37x, 37y, 37z Paragr. 4 of the German Securities Trading Act and Section 42 Paragr. 1 of the German Stock Exchange Act.
